Loading
A phase 1/2 trial of anlotinib and sintilimab in pancreatic cancer, run by Fujian Provincial Hospital, now recruiting.
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer is a phase 1/2, interventional study registered as NCT06761027 by Fujian Provincial Hospital, with a registry enrolment figure of 29 participants, started 2024-12-23 and due to reach its primary completion in 2027-03. Interventions recorded: Anlotinib combined with Sintilimab. Conditions listed: Locally Advanced Pancreatic Cancer; Metastatic Pancreatic Cancer. Primary outcome: Objective response rate, ORR. Pancreatic eligibility wording from the registry: "Patients with locally advanced or metastatic pancreatic cancer diagnosed by histology or cytology;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Sintilimab, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.